# US 2013/0158088 A1 · Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158088 A1
- Document ID: US20130158088A1
- Status: Published application
- Kind: A1
- Application number: 13/818,346
- Filed: 2011-08-22
- Published: 2013-06-20
- Earliest claimed: 2010-08-24
- Assignees: Novartis AG
- Inventors: Diego Albrecht; Priyamvada Chandra; Sven Godtfredsen; Pierre Jordaan; Martin Lefkowitz
- Web page: https://patentgrep.com/patent/US20130158088A1

## CPC

- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/221: with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A method of treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy comprising administering to said mammal:
a) a pharmaceutical composition comprising a therapeutically effective amount of the compound of the formula:
[(A1)(A2)](C)y·x H2O (I)
wherein
A1 is S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form;
A2 is (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form;
(Cat) is a cation;
y is 1 to 3; and
x is 0 to 3;
or
b) a pharmaceutical composition comprising a therapeutically effective amount of
(i) valsartan or a pharmaceutically acceptable salt thereof; and
(ii) N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester or (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionyl amino)-2-methyl-pentanoic acid or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15 wherein the mammal is a human.

### Claim 17 (depends on 15)

The method of claim 15 wherein the compound of formula (I) is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate.

### Claim 18 (depends on 15)

The method of claim 15 wherein the anticoagulant treatment comprises administration of warfarin or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 15)

The method of claim 15 wherein the heart failure is congestive heart failure, left heart failure, right heart failure, chronic heart failure, advanced heart failure, acute heart failure, acute decompensated heart failure, heart failure with reduced ejection fraction, or heart failure with preserved ejection fraction.

### Claim 20 (depends on 18)

The method of claim 18 wherein the heart failure is congestive heart failure, left heart failure, right heart failure, chronic heart failure, advanced heart failure, acute heart failure, acute decompensated heart failure, heart failure with reduced ejection fraction, or heart failure with preserved ejection fraction.

### Claim 21 (depends on 16)

The method of claim 16 wherein the therapeutically effective amount of compound of formula (I) is effective to induce at least one physiological effect in the human subject including vasodilation, diuresis, natriuresis and combinations thereof.

### Claim 22 (depends on 16)

The method of claim 16 wherein the therapeutically effective amount of compound of formula (I) is effective to inhibit one or more physiological events in the human subject including vasoconstriction, hypertrophy, hyperproliferation, edema and combinations thereof.

### Claim 23 (depends on 16)

The method of claim 16 wherein the human has previously suffered a myocardial infarction.

### Claim 24 (depends on 16)

The method of claim 16 wherein the human has an enlarged heart.

### Claim 25 (depends on 16)

The method of claim 16 wherein the human has atherosclerosis.

### Claim 26 (depends on 16)

The method of any of claim 16 wherein the human has hypertension.

### Claim 27 (depends on 15)

The method of claim 15 wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable carriers in combination with the compound of formula (I).

### Claim 28 (depends on 15)

The method of claim 15 wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable carriers in combination with the compounds (i)/(ii).

### Claim 29

A method of treating hypertension and/or preventing or treating heart failure in a human receiving anti-coagulant therapy comprising administering to said human a pharmaceutical composition comprising a therapeutically effective amount of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate, wherein the anticoagulant treatment comprises administration of warfarin or a pharmaceutically acceptable salt thereof.

### Claim 30

A pharmaceutical combination for treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy comprising:
a) a therapeutically effective amount of the compound of the formula:
[(A1)(A2)](C)y·x H2O (I)
wherein
A1 is S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form;
A2 is (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form;
(Cat) is a cation;
y is 1 to 3; and
x is 0 to 3;
or
b) a therapeutically effective amount of
(i) valsartan or a pharmaceutically acceptable salt thereof; and
(ii) N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester or (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionyl amino)-2-methyl-pentanoic acid or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 29)

The pharmaceutical combination of claim 29 wherein the compounds of formulas (i) are (ii) are present to with one or more pharmaceutically acceptable carriers.
